A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)

Inclusion Criteria PART 1 * Has locally advanced or metastatic clear cell renal cell carcinoma (ccRCC) and has progressed during treatment with at least one prior therapeutic regimen * Has a life expectancy of ≥ 3 months * Has adequate organ function * Able to swallow oral medications PART 2 - In addition to PART 1 * Received no more than three prior systemic treatment regimens in the advanced or metastatic setting * Must have received at least one but not more than two prior anti-angiogenic therapy regimens PART 3 - In addition to PART 1 * Must have received at least one vascular endothelial growth factor receptor (VEGFR) targeting tyrosine kinase inhibitor Exclusion Criteria PART 1 * Has a history of untreated brain metastasis or history of leptomeningeal disease or spinal cord compression * Has failed to recover from the reversible effects of prior anticancer therapy * Has uncontrolled or poorly controlled hypertension * Is receiving warfarin anticoagulant therapy or expected to require warfarin * Has had any major cardiovascular event within 6 months prior to study drug administration * Has any other clinically significant cardiac, respiratory, or other medical or psychiatric condition that might interfere with participation in the trial or interfere with the interpretation of trial results * Has had major surgery within 4 weeks before first study drug administration * Has known human immunodeficiency virus (HIV) infection * Has an active infection requiring systemic treatment * Is participating in another therapeutic clinical trial PART 2 - In addition to PART 1 * Has received prior immunotherapy * Has any active or recent history of a known or suspected autoimmune disease PART 3 - In addition to PART 1 * Has gastrointestinal (GI) disorders * Has any history of congenital long QT syndrome